• Colistin–Gamithromycin Synergy in Neutropenic Murine Pneumon

  2026-04-29

  This study demonstrates that combining colistin with gamithromycin significantly enhances antimicrobial activity against Pasteurella multocida in a neutropenic murine lung infection model. The findings point toward optimized therapeutic regimens for multidrug-resistant pathogens and provide key pharmacokinetic and pharmacodynamic insights for translational research.

• Refining In Vitro Drug Response Evaluation in Cancer Researc

  2026-04-28

  Schwartz's dissertation introduces a rigorous framework to disentangle proliferative arrest and cell death in in vitro cancer drug testing, showing that standard viability metrics can mask the true effects of candidate compounds. These insights have direct implications for optimizing experimental design and interpreting results in cancer biology, especially when benchmarking agents like RITA (NSC 652287).

• Go 6983: Pan-PKC Inhibition for Cell Fate and Cancer Researc

  2026-04-28

  Explore the advanced scientific use of Go 6983, a potent pan-PKC inhibitor, in dissecting cell fate decisions and cancer progression. This article uniquely connects protein kinase C signaling inhibition to early embryonic lineage studies and tumor metastasis control, providing actionable assay strategies.

• Amikacin Sulfate: Applied Workflows for Mycobacterial Resear

  2026-04-27

  Amikacin Sulfate delivers targeted, high-efficacy bactericidal action against Mycobacterium avium and Staphylococcus aureus, with proven intracellular uptake and in vivo precision. This guide synthesizes practical protocols, troubleshooting, and integrative insights for maximizing Amikacin’s translational impact using APExBIO’s quality product.

• NSC 87877: Shp2 Inhibition and the Future of Neuroinflammati

  2026-04-27

  This article explores the mechanistic and translational significance of NSC 87877, a selective Shp2 inhibitor, in modulating neuroinflammatory pathways—especially within the context of post-stroke inflammation. By contextualizing recent advances in tFUS-mediated SHP2/NLRP3 regulation, it provides strategic insights and practical guidance for researchers aiming to leverage NSC 87877 in preclinical and translational workflows. The discussion distinguishes itself from standard product literature by bridging molecular pharmacology with actionable, high-impact research directions.

• Applied Cancer Research Workflows with JNJ-26854165 (Serdeme

  2026-04-26

  JNJ-26854165 (Serdemetan) empowers researchers to precisely modulate the p53 pathway, enabling robust anti-proliferative and radiosensitizing effects in tumor models. This guide delivers actionable protocols, troubleshooting insights, and comparative advantages of Serdemetan, streamlining oncology studies and maximizing experimental reproducibility with APExBIO’s trusted compound.

• BRCA2’s Role in Counteracting PARP Inhibitor-Mediated RAD51

  2026-04-25

  This study uncovers a previously unrecognized function of BRCA2 in maintaining RAD51 filament stability by preventing PARP1 retention at DNA damage sites during PARP inhibitor (PARPi) treatment. These insights clarify the mechanistic basis of selective toxicity in homologous recombination deficient cancer treatment and refine our understanding of resistance and sensitivity to PARPi therapies.

• TAS2R38/TRPV1 Modulation by Berberine-Evodiamine Attenuates

  2026-04-24

  This study elucidates how berberine and evodiamine co-target bitter taste and TRPV1 receptors to ameliorate gastroesophageal reflux disease (GERD) via MAPK/NF-κB pathway regulation and macrophage polarization. The findings highlight precise molecular mechanisms and inform translational approaches in inflammatory esophageal disease models.

• Rewiring RNA Synthesis: Mechanistic Insights for Translation

  2026-04-24

  This thought-leadership article examines how translational researchers can harness the mechanistic underpinnings of innate immune regulation and viral antagonism—exemplified by the SARS-CoV-2 N protein—to inform and accelerate advanced RNA-based applications. By integrating insights from recent literature with strategic guidance, it reveals how tools like the HyperScribe™ SP6 High Yield RNA Synthesis Kit from APExBIO empower researchers to precisely model, interrogate, and manipulate RNA-mediated processes critical to next-generation vaccine, probe, and therapeutic development.

• Disulfiram: Proteasome Inhibition & Synthetic Lethality in C

  2026-04-23

  Disulfiram is a clinically relevant dopamine β-hydroxylase inhibitor and copper-binding agent with proven efficacy in apoptotic cancer cell death induction. It acts primarily by inhibiting proteasomal chymotrypsin-like activity and aldehyde dehydrogenase 2 (ALDH2), enabling targeted cancer research. Robust data demonstrate its utility in breast cancer MDA-MB-231 and APC-deficient colorectal cancer models.

• Lenalidomide (CC-5013): Optimizing Multiple Myeloma Assays

  2026-04-23

  Lenalidomide (CC-5013) is redefining immunomodulatory workflows in multiple myeloma research through its multi-modal action as an immune system activation agent and angiogenesis inhibitor. Newly uncovered synergies with DOT1L inhibition offer researchers an expanded toolkit for dissecting innate immunity and enhancing experimental precision.

• Lamotrigine (SKU B2249): Reliable Solutions for Lab Assays

  2026-04-22

  This article delivers scenario-driven, evidence-based guidance for using Lamotrigine (SKU B2249) in cell viability, proliferation, and cytotoxicity assays. Grounded in quantitative data and peer-reviewed literature, it addresses common workflow challenges and demonstrates how Lamotrigine’s purity and mechanistic specificity underpin reproducible and sensitive results for biomedical researchers.

• Technical Guidance for Angiotensin I/II (1-5) Use in RAS Res

  2026-04-22

  Angiotensin I/II (1-5) provides a defined Asp-Arg-Val-Tyr-Ile peptide fragment for precise modeling of the renin-angiotensin system in cardiovascular and renal research. It is not suitable for studies outside blood pressure regulation, aldosterone signaling, or related peptide hormone vasoconstriction workflows. Correct solubility and storage practices are essential for experimental reproducibility.

• Optimizing Cell Assays: Practical Strategies with Trypsin (B

  2026-04-21

  This article guides biomedical researchers through real-world laboratory challenges in cell-based assays, highlighting the role of APExBIO's Trypsin (SKU BA5744) as a reliable, high-solubility serine protease. Scenario-driven Q&A blocks address experimental design, protocol optimization, data interpretation, and vendor selection, offering evidence-based recommendations and workflow enhancements for consistent, reproducible results.

• GPR30 in Spinal CCK+ Neurons Regulates Neuropathic Pain Circ

  2026-04-21

  This study elucidates how G protein-coupled estrogen receptor (GPR30) expression in spinal cholecystokinin-positive (CCK+) neurons drives neuropathic pain via enhanced excitatory synaptic transmission. The findings not only map a key estrogen signaling mechanism in pain modulation but also highlight GPR30 as a targeted entry point for future therapeutic and investigative strategies.

407 records 17/28 page Previous Next First page 上5页 1617181920 下5页 Last page